Clinical characteristics of 2 groups of HIV-associated aggressive B lymphomas with or without MYC rearrangement
| . | Patients with MYC+, n = 43 . | Patients with MYC–, n = 112 . | Total, N = 155 . | P value . |
|---|---|---|---|---|
| Median age (range), y | 46 (26-74) | 48 (23-83) | 47 (23-83) | ns |
| Age >60 y | 7 (16%) | 14 (12%) | 21 (14%) | ns |
| Male sex | 37 (86%) | 88 (79%) | 125 (81%) | ns |
| Stage III-IV | 40/43 (93%) | 88/110∗ (80%) | 128/155 (82%) | .05 |
| B symptoms | 22/43 (51%) | 55/108∗ (51%) | 77/151∗ (51%) | ns |
| Increased LDH | 30/39∗ (77%) | 70/104∗ (67%) | 100/143∗ (70%) | ns |
| Extranodal sites | .05 | |||
| ≤ 2 | 19/38∗ (50%) | 68/100∗ (68%) | 87/138∗ (63%) | |
| > 2 | 19/38∗ (50%) | 32/100∗ (32%) | 51/138∗ (37%) | |
| CNS involvement | 4/29∗ (14%) | 2/64∗ (3%) | 6/93∗ (6%) | .052 |
| Kidney/adrenal gland involvement | 8/29∗ (27%) | 8/64∗ (12%) | 16/93∗ (17%) | .074 |
| ECOG performance status ≥2 | 19/34∗ (56%) | 42/87∗ (48%) | 61/121∗ (50%) | ns |
| IPI intermediate high-high | 23/39∗ (64%) | 49/92∗ (53%) | 72/131∗ (55%) | ns |
| HCV seropositivity | 11/38∗ (29%) | 34/93∗ (36%) | 45/131∗ (34%) | ns |
| Positive HBsAg | 3/36∗ (8%) | 8/89∗ (9%) | 11/125∗ (9%) | ns |
| Median CD4+ cell baseline (range), n/mmc | 215 (32-1170) | 198 (8-990) | 198 (8-1170) | ns |
| CD4+ cell <200/mmc | 19/38∗ (50%) | 51/100∗ (51%) | 70/138∗ (51%) | ns |
| Detectable HIV load | 24/40∗ (60%) | 65/107∗ (61%) | 89/147∗ (60%) | ns |
| AIDS before lymphoma diagnosis | 5/41∗ (12%) | 30/111∗ (27%) | 35/152∗ (23%) | .054 |
| cART before lymphoma diagnosis | 20/42∗ (48%) | 62/110∗ (56%) | 32/152∗ (54%) | ns |
| . | Patients with MYC+, n = 43 . | Patients with MYC–, n = 112 . | Total, N = 155 . | P value . |
|---|---|---|---|---|
| Median age (range), y | 46 (26-74) | 48 (23-83) | 47 (23-83) | ns |
| Age >60 y | 7 (16%) | 14 (12%) | 21 (14%) | ns |
| Male sex | 37 (86%) | 88 (79%) | 125 (81%) | ns |
| Stage III-IV | 40/43 (93%) | 88/110∗ (80%) | 128/155 (82%) | .05 |
| B symptoms | 22/43 (51%) | 55/108∗ (51%) | 77/151∗ (51%) | ns |
| Increased LDH | 30/39∗ (77%) | 70/104∗ (67%) | 100/143∗ (70%) | ns |
| Extranodal sites | .05 | |||
| ≤ 2 | 19/38∗ (50%) | 68/100∗ (68%) | 87/138∗ (63%) | |
| > 2 | 19/38∗ (50%) | 32/100∗ (32%) | 51/138∗ (37%) | |
| CNS involvement | 4/29∗ (14%) | 2/64∗ (3%) | 6/93∗ (6%) | .052 |
| Kidney/adrenal gland involvement | 8/29∗ (27%) | 8/64∗ (12%) | 16/93∗ (17%) | .074 |
| ECOG performance status ≥2 | 19/34∗ (56%) | 42/87∗ (48%) | 61/121∗ (50%) | ns |
| IPI intermediate high-high | 23/39∗ (64%) | 49/92∗ (53%) | 72/131∗ (55%) | ns |
| HCV seropositivity | 11/38∗ (29%) | 34/93∗ (36%) | 45/131∗ (34%) | ns |
| Positive HBsAg | 3/36∗ (8%) | 8/89∗ (9%) | 11/125∗ (9%) | ns |
| Median CD4+ cell baseline (range), n/mmc | 215 (32-1170) | 198 (8-990) | 198 (8-1170) | ns |
| CD4+ cell <200/mmc | 19/38∗ (50%) | 51/100∗ (51%) | 70/138∗ (51%) | ns |
| Detectable HIV load | 24/40∗ (60%) | 65/107∗ (61%) | 89/147∗ (60%) | ns |
| AIDS before lymphoma diagnosis | 5/41∗ (12%) | 30/111∗ (27%) | 35/152∗ (23%) | .054 |
| cART before lymphoma diagnosis | 20/42∗ (48%) | 62/110∗ (56%) | 32/152∗ (54%) | ns |
HCV, Hepatitis C Virus; HBsAg, Hepatitis B surface antigen; ns, not significant.
Denominators regard assessed patients.